Rheumatology Studies

SIMPONI® (golimumab) was developed to fit with patient needs and lifestyle, whilst continuing to improve functionality and disease outcomes. It is the first and only subcutaneous anti-TNF therapy with convenient once-monthly dosing from day one, licenced for Rheumatoid Arthritis (RA), Axial Spondyloarthritis, Non- Radiographic Axial Spondyloarthritis (nr-Axial SpA) and Psoriatic Arthritis (PsA) within Rheumatology.1

What are the GO ‘studies’?:

The ‘GO studies’ evaluated the efficacy and safety of SIMPONI® (golimumab) in patients across a variety of rheumatological conditions and generated 5 year data in three indications.2,3,4,5

Rheumatoid Arthritis (RA)

Find out more about RA patient outcomes at five years and on the Real World Swedish Registry.

Axial Spondyloarthritis

Find out more about Ankylosing Spondylitis (AS) patient outcomes at five years.

Psoriatic Arthritis (PsA)

Find out more about PsA patient outcomes at five years.

IE-GOL-00049|Date of preparation: November 2020